Home

HOLLINGS RENTON

CIK 1187333 · President and CEO · last filed 2026-06-17

HOLLINGS RENTON is a President and CEO who has filed 89 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for ANAB, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$15.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $624.5K across reported positions. 25 SEC filings were submitted jointly with ANAPTYSBIO, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$624.5K

Companies

8

Total Filings

89

Lifetime Open-Market Net

-$15.08M

Filer Profile

Reported Address
10421 PACIFIC CENTER COURT
SUITE 200
SAN DIEGO, CA 92121
Related Filers
ANAPTYSBIO, INC — 25 joint filings, latest 2026-06-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ANAB Director 10,995 $56.80 $624.5K -$1.37M 19 2026-06-17
ZYME Director — $29.19 — $0 5 2023-12-08
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted Director 0 — — -$875.4K 14 2020-07-02
CEPHEID (CPHD) Delisted Director 0 — — -$4.29M 23 2016-11-07
KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted Director — — — $0 3 2015-10-02
RIGL Director — $48.67 — $0 7 2013-05-28
AFFYMAX INC (AFFY) Delisted Director — — — $0 4 2012-06-18
ONYX PHARMACEUTICALS INC (ONXX) Delisted President and CEO 232,490 — — -$8.55M 9 2008-02-26

Recent Filings

89 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-17 ANAB Exer (M) +6,030 $0 EDGAR
2026-04-22 ANAB Mixed — $0 EDGAR
2026-01-08 ANAB Grant (A) — $0 EDGAR
2025-08-12 ANAB Mixed — -$129.8K EDGAR
2025-08-08 ANAB Notice (144) −10,231 -$200.7K EDGAR
2025-07-03 ANAB Mixed — -$348.2K EDGAR
2025-07-02 ANAB Notice (144) −20,925 -$493.2K EDGAR
2025-06-20 ANAB Sell (S) −3,015 -$72.3K EDGAR
2025-06-18 ANAB Notice (144) −3,015 -$72.3K EDGAR
2025-06-17 ANAB Exer (M) +6,030 $0 EDGAR
Showing 1–10 of 89
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.